HK1223547A1 - Methods for the treatment of cancer - Google Patents
Methods for the treatment of cancerInfo
- Publication number
- HK1223547A1 HK1223547A1 HK16111783.0A HK16111783A HK1223547A1 HK 1223547 A1 HK1223547 A1 HK 1223547A1 HK 16111783 A HK16111783 A HK 16111783A HK 1223547 A1 HK1223547 A1 HK 1223547A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819505P | 2013-05-03 | 2013-05-03 | |
| PCT/US2014/036651 WO2014179738A1 (en) | 2013-05-03 | 2014-05-02 | Methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1223547A1 true HK1223547A1 (en) | 2017-08-04 |
Family
ID=51843995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16111783.0A HK1223547A1 (en) | 2013-05-03 | 2016-10-12 | Methods for the treatment of cancer |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2991650A4 (en) |
| JP (2) | JP2016522188A (en) |
| KR (1) | KR102337598B1 (en) |
| CN (1) | CN105492007A (en) |
| HK (1) | HK1223547A1 (en) |
| WO (1) | WO2014179738A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018103064A (en) * | 2015-06-29 | 2019-07-30 | Синдакс Фармасьютикалз, Инк. | HDAC INHIBITOR COMBINATION AND ANTI-PD-L1 ANTIBODIES FOR TREATING A MALIGNANT TUMOR |
| WO2018016563A1 (en) * | 2016-07-20 | 2018-01-25 | Eisai R&D Management Co., Ltd. | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer |
| JP2020520943A (en) * | 2017-05-19 | 2020-07-16 | シンダックス ファーマシューティカルズ， インコーポレイテッド | Combination therapy |
| MA52778A (en) * | 2018-06-06 | 2021-04-21 | Arena Pharm Inc | METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH THE S1P1 RECEPTOR |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1861094A4 (en) * | 2005-03-11 | 2014-06-11 | Univ Colorado | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| AU2007272951A1 (en) * | 2006-07-11 | 2008-01-17 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
| WO2009067500A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac |
| CA2719115A1 (en) * | 2008-03-07 | 2009-09-11 | Pfizer Inc. | Methods, dosage forms, and kits for administering ziprasidone without food |
| US20110182888A1 (en) * | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| EA201201474A1 (en) * | 2011-09-02 | 2013-08-30 | Синдэкс Фармасьютикалс, Инк. | METHODS OF TREATMENT BREAST CANCER |
-
2014
- 2014-05-02 CN CN201480038420.7A patent/CN105492007A/en active Pending
- 2014-05-02 EP EP14791444.4A patent/EP2991650A4/en not_active Withdrawn
- 2014-05-02 KR KR1020157033947A patent/KR102337598B1/en active IP Right Grant
- 2014-05-02 WO PCT/US2014/036651 patent/WO2014179738A1/en active Application Filing
- 2014-05-02 JP JP2016512076A patent/JP2016522188A/en active Pending
-
2016
- 2016-10-12 HK HK16111783.0A patent/HK1223547A1/en unknown
-
2019
- 2019-02-15 JP JP2019026073A patent/JP6860949B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014179738A1 (en) | 2014-11-06 |
| CN105492007A (en) | 2016-04-13 |
| JP2016522188A (en) | 2016-07-28 |
| KR20160003182A (en) | 2016-01-08 |
| JP6860949B2 (en) | 2021-04-21 |
| JP2019112416A (en) | 2019-07-11 |
| EP2991650A1 (en) | 2016-03-09 |
| EP2991650A4 (en) | 2017-01-25 |
| KR102337598B1 (en) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273090B (en) | Methods and compositions for the treatment of cancer | |
| PL3033086T3 (en) | Combination therapy for the treatment of cancer | |
| HK1220155A1 (en) | Methods for treating cancer | |
| SG10201801965RA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| HK1213817A1 (en) | Methods of treating cancer | |
| HK1222548A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1219737A1 (en) | Novel compounds for the treatment of cancer | |
| EP3008212A4 (en) | Methods of treatment of cancer | |
| HK1219513A1 (en) | Methods of treating cancer | |
| HK1223547A1 (en) | Methods for the treatment of cancer | |
| IL245551A0 (en) | Antibodies anti matriptase for the treatment of cancer | |
| HUE048625T2 (en) | Methods for treating cancer | |
| GB201403083D0 (en) | Treatment of cancer | |
| HK1221681A1 (en) | Methods for the treatment of neurodegeneration | |
| HK1232118A1 (en) | Treatment of cancer | |
| PL3016948T3 (en) | 2-acylaminothiazoles for the treatment of cancer | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201300546D0 (en) | Cancer Treatment |